AODWE-005 Golimumab induction for moderate to severe ulcerative colitis: patient-reported outcomes of partial mayo score results from the go-colitis study

Abstract

IntroductionGO-COLITIS is a multicentre, open-label, single-arm, phase 4 study (NCT02092285; 2013-004583-56) that measured efficacy of subcutaneous golimumab (GLM) in anti-tumour necrosis factor-naïve UK patients with moderate to severe ulcerative colitis...